IDEAYA Biosciences, Inc. $IDYA Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC lowered its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 3.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,073,583 shares of the company’s stock after selling 76,450 shares during the period. Geode Capital Management LLC owned approximately 2.37% of IDEAYA Biosciences worth $71,695,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Fisher Asset Management LLC increased its holdings in shares of IDEAYA Biosciences by 3.2% in the fourth quarter. Fisher Asset Management LLC now owns 889,633 shares of the company’s stock valued at $30,755,000 after purchasing an additional 27,425 shares during the period. Legato Capital Management LLC acquired a new position in shares of IDEAYA Biosciences in the fourth quarter valued at approximately $826,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of IDEAYA Biosciences in the fourth quarter valued at approximately $743,000. Global Retirement Partners LLC acquired a new position in shares of IDEAYA Biosciences in the fourth quarter valued at approximately $61,000. Finally, Atle Fund Management AB acquired a new position in shares of IDEAYA Biosciences in the fourth quarter valued at approximately $3,368,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Performance

IDYA opened at $31.48 on Tuesday. The business’s fifty day moving average is $30.18 and its two-hundred day moving average is $32.62. The company has a market cap of $2.77 billion, a price-to-earnings ratio of -19.68 and a beta of -0.04. IDEAYA Biosciences, Inc. has a one year low of $20.50 and a one year high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its earnings results on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The business had revenue of $6.56 million during the quarter, compared to the consensus estimate of $5.04 million. The business’s quarterly revenue was down 39.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.82) EPS. On average, analysts predict that IDEAYA Biosciences, Inc. will post -4.27 EPS for the current fiscal year.

Analyst Ratings Changes

IDYA has been the topic of a number of recent research reports. Citigroup reissued a “market outperform” rating on shares of IDEAYA Biosciences in a report on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Tuesday, April 21st. Wells Fargo & Company boosted their target price on IDEAYA Biosciences from $44.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, April 14th. The Goldman Sachs Group lifted their price target on IDEAYA Biosciences from $31.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, April 14th. Finally, Wall Street Zen downgraded IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Fifteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $50.69.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.